Among NSCLC, patients with high Jab1/COPS5 expression levels have poor outcomes with a 5-year overall survival rate of 43.9%, compared with 63.1% for patients who have low level of Jab1 expression (Osoegawa et al., 2006). Here, COPS5 is linked to non-small cell lung carcinoma.